デフォルト表紙
市場調査レポート
商品コード
1326547

T細胞療法の世界市場規模調査&予測、タイプ別、適応症別、最終用途別、地域別分析、2023-2030年

Global T-Cell therapy Market Size study & Forecast, by Type (CAR T-Cell therapy, T-Cell Receptor-Based), by Indication (Lymphoma, Acute Lymphocytic Leukemia, Others), by End User (Hospitals, Cancer Treatment Centers) and Regional Analysis, 2023-2030

出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=159.45円
T細胞療法の世界市場規模調査&予測、タイプ別、適応症別、最終用途別、地域別分析、2023-2030年
出版日: 2023年07月28日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のT細胞療法市場は、2022年に約28億米ドルと評価され、予測期間2023-2030年には18.3%以上の健全な成長率で成長すると予測されています。

T細胞療法は革新的でカスタマイズされた免疫療法の一種であり、患者自身の免疫システムの力を利用することで、がん細胞やその他の病気を分離・根絶しようとするものです。白血球の一種であるT細胞は、患者の体内から抽出され、特定のがん細胞や病気の標的を認識して破壊する能力を向上させるために、実験室で改変されます。T細胞療法市場規模の成長を牽引している主な理由は、がん罹患率の増加、高齢者人口の増加、がん症状治療のためのさまざまな細胞療法技術の使用量の増加です。さらに、T細胞療法市場は継続的な変化と拡大が特徴であり、これは研究開発イニシアチブの継続と臨床開発段階にある複数の薬剤の利用可能性が市場拡大を後押ししていることが主な要因です。さらに、メーカーによる販売促進活動の増加や、適切ながん治療薬に関する一般人口の知識の増加が、予測期間を通じてT細胞療法の普及を後押ししています。

さらに、がん有病率の上昇がT細胞療法市場の成長を促進する重要な要因となっています。がんは世界的に重大な健康問題であり続け、毎年診断される人の数が増加しています。このようながん罹患率の増加は、革新的で効果的な治療オプションに対する強い需要を生み出しています。2022年の世界がん研究基金によると、世界のがん患者数は1,810万人と推定されます。2020年には男性が930万人、女性が880万人を占める。世界的に最も頻度の高い悪性腫瘍は乳がんと肺がんで、2020年に新たに診断される症例のそれぞれ12.5%と12.2%を占める。肺がんは世界的に男性で最も頻度の高い疾患で、2020年に新たに診断される症例の15.4%を占めました。大腸がんは、2020年に新たに診断される症例の10.7%を占める190万症例で、3番目に頻度の高いがんでした。さらに、規制当局による承認の増加や研究開発活動の増加は、予測期間中の胸腺細胞療法市場の成長に有益な機会を提供しています。しかし、T細胞療法のコストが高いことが、2023-2030年の予測期間を通じて市場の成長を阻害しています。

T細胞療法の世界市場調査において考慮した主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカなどです。北米は、がん患者の増加、民間および政府機関による資金提供の拡大、確立された研究・商業化基盤により、2022年の市場を独占しました。さらに、北米では高齢者人口の増加により、がんの罹患頻度が高くなり、適切な治療法の必要性が高まっています。2022年の米国国立衛生研究所によると、米国では2020年に1,918,030人の新規がん患者と609,360人のがん死亡が予想され、がん死亡の主因である肺がんは毎日350人近い死亡者を出しています。アジア太平洋地域は、この地域における研究開発の増加により、予測期間中に大きく成長すると予想されます。さらに、ヘルスケアインフラの拡大や政府の取り組みが、この地域の市場成長率を加速させています。例えば、中国の国立医学図書館は、2022年には約88,249件の白血病の新規症例(男性50,213件、女性38,036件)が発生すると予測しています。

本調査の目的は、近年における様々なセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面の両方を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

第2章 世界のT細胞療法市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 業界の進化
    • 調査範囲
  • 調査対象年
  • 通貨換算レート

第3章 T細胞療法の世界市場力学

  • T細胞療法市場の影響分析(2020-2030年)
    • 市場促進要因
      • がん有病率の増加
      • 高齢者人口の増加
    • 市場の課題
      • T細胞療法の高コスト
      • 厳しい政府規制
    • 市場機会
      • 新製品開発
      • 研究開発活動の増加

第4章 世界のT細胞療法市場産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォース影響分析
  • PEST分析
    • 政治
    • 経済
    • 社会
    • 技術
    • 環境
    • 法律
  • 主な投資機会
  • 主要成功戦略
  • COVID-19影響分析
  • 破壊的動向
  • 業界専門家の視点
  • アナリストの結論・提言

第5章 T細胞療法の世界市場:タイプ別

  • 市場スナップショット
  • T細胞療法の世界市場:タイプ別、実績 - ポテンシャル分析
  • T細胞療法の世界市場:タイプ別、推定・予測2020-2030年
  • T細胞療法の世界市場、サブセグメント別分析
    • CAR T細胞療法
    • T細胞受容体ベース

第6章 T細胞療法の世界市場:適応症別

  • 市場スナップショット
  • T細胞療法の世界市場:適応症別、実績 - ポテンシャル分析
  • T細胞療法の世界市場、適応症別、推定・予測2020-2030年
  • T細胞療法の世界市場、サブセグメント別分析
    • リンパ腫
    • 急性リンパ性白血病
    • その他

第7章 T細胞療法の世界市場:最終用途別

  • 市場スナップショット
  • T細胞療法の世界市場:最終用途別、実績 - ポテンシャル分析
  • T細胞療法の世界市場:最終用途別、推定・予測2020~2030年
  • T細胞療法の世界市場、サブセグメント別分析
    • 病院
    • がん治療センター

第8章 T細胞療法の世界市場:地域別分析

  • 主要上位国
  • 主な新興国
  • T細胞療法の世界市場、地域別市場スナップショット
  • 北米
    • 米国
      • タイプの推定・予測、2020-2030年
      • 適応症の推定・予測、2020-2030年
      • 最終用途の推定・予測、2020~2030年
    • カナダ
  • 欧州T細胞療法市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋T細胞療法市場スナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカのT細胞療法市場スナップショット
    • ブラジル
    • メキシコ
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • その他中東とアフリカ

第9章 競合情報

  • 主要企業のSWOT分析
  • 主要市場戦略
  • 企業プロファイル
    • Bristol-Myers Squibb Company
      • 主要情報
      • 概要
      • 財務(データの入手可能性によります)
      • 製品概要
      • 最近の動向
    • Caribou Biosciences, Inc
    • Cartesian Therapeutics, Inc.
    • Johnson & Johnson Pvt Ltd.
    • Cellectis, Inc.
    • Autolus Therapeutics
    • Immunocore Ltd.
    • Gilead Sciences, Inc.
    • Novartis AG
    • Celyad Oncology SA

第10章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • 検証
    • 出版
  • 調査属性
  • 調査前提条件
図表

LIST OF TABLES

  • TABLE 1. Global T-Cell therapy Market, report scope
  • TABLE 2. Global T-Cell therapy Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global T-Cell therapy Market estimates & forecasts by Type 2020-2030 (USD Billion)
  • TABLE 4. Global T-Cell therapy Market estimates & forecasts by Indication 2020-2030 (USD Billion)
  • TABLE 5. Global T-Cell therapy Market estimates & forecasts by End Use 2020-2030 (USD Billion)
  • TABLE 6. Global T-Cell therapy Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 7. Global T-Cell therapy Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8. Global T-Cell therapy Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9. Global T-Cell therapy Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global T-Cell therapy Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global T-Cell therapy Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global T-Cell therapy Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global T-Cell therapy Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. Global T-Cell therapy Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. Global T-Cell therapy Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16. U.S. T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 17. U.S. T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 18. U.S. T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 19. Canada T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 20. Canada T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 21. Canada T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 22. UK T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 23. UK T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 24. UK T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 25. Germany T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 26. Germany T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 27. Germany T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 28. France T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 29. France T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 30. France T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 31. Italy T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 32. Italy T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 33. Italy T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 34. Spain T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 35. Spain T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 36. Spain T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 37. RoE T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 38. RoE T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 39. RoE T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 40. China T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 41. China T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 42. China T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 43. India T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 44. India T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 45. India T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 46. Japan T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 47. Japan T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 48. Japan T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 49. South Korea T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 50. South Korea T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 51. South Korea T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 52. Australia T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 53. Australia T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 54. Australia T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 55. RoAPAC T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 56. RoAPAC T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 57. RoAPAC T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 58. Brazil T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 59. Brazil T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 60. Brazil T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 61. Mexico T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 62. Mexico T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 63. Mexico T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 64. RoLA T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 65. RoLA T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 66. RoLA T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 67. Saudi Arabia T-Cell therapy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 68. South Africa T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 69. RoMEA T-Cell therapy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 70. List of secondary sources, used in the study of global T-Cell therapy Market
  • TABLE 71. List of primary sources, used in the study of global T-Cell therapy Market
  • TABLE 72. Years considered for the study
  • TABLE 73. Exchange rates considered

List of tables and figures are dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

  • FIG 1. Global T-Cell therapy Market, research methodology
  • FIG 2. Global T-Cell therapy Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global T-Cell therapy Market, key trends 2022
  • FIG 5. Global T-Cell therapy Market, growth prospects 2023-2030
  • FIG 6. Global T-Cell therapy Market, porters 5 force model
  • FIG 7. Global T-Cell therapy Market, pest analysis
  • FIG 8. Global T-Cell therapy Market, value chain analysis
  • FIG 9. Global T-Cell therapy Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global T-Cell therapy Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global T-Cell therapy Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global T-Cell therapy Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global T-Cell therapy Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global T-Cell therapy Market, regional snapshot 2020 & 2030
  • FIG 15. North America T-Cell therapy Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe T-Cell therapy Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific T-Cell therapy Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America T-Cell therapy Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa T-Cell therapy Market 2020 & 2030 (USD Billion)

List of tables and figures are dummy in nature, final lists may vary in the final deliverable

目次

Global T-Cell therapy Market is valued at approximately USD 2.8 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 18.3% over the forecast period 2023-2030. T-cell therapy is an innovative and customized kind of immunotherapy that tries to isolate and eradicate cancer cells or other illnesses by harnessing the strength of the patient's own immune system. T cells, a kind of white blood cell, are extracted from a patient's body and modified in a laboratory to improve their capacity to recognize and destroy certain cancer cells or disease targets. The main reasons driving the growth of the T-cell therapy market size are an increase in cancer prevalence, an increase in the elderly population, and an increase in the usage of different cell therapy technologies to treat cancer symptoms. Furthermore, the T-cell therapy market is characterized by continual change and expansion, which is largely driven by continuing R&D initiatives and the availability of several medications in the clinical development phase is propelling market expansion. In addition, a rise in promotional activities by manufacturers and an increase in general population knowledge of suitable cancer treatment pharmaceuticals are likely to fuel their adoption all over the projection period.

Moreover, the rising prevalence of cancer has been a key factor in driving the growth of the T-cell therapy market. Cancer continues to be a significant global health concern, with a growing number of individuals being diagnosed each year. This increasing incidence of cancer has created a strong demand for innovative and effective treatment options. According to the World Cancer Research Fund in 2022, there are estimated 18.1 million cancer cases worldwide. Men accounted for 9.3 million of the cases, while women accounted for 8.8 million in 2020. Breast and lung cancers were the most frequent malignancies globally, accounting for 12.5% and 12.2% of all new cases diagnosed in 2020, respectively. Lung cancer was the most frequent disease in men globally, accounting for 15.4% of all new cases diagnosed in 2020. Colorectal cancer was the third most frequent cancer in 2020, with 1.9 million new cases, accounting for 10.7% of all new cases. Additionally, the increasing approvals by regulatory agencies and the increase in the number of research and development activities further provide beneficial opportunities for the thymus cell therapy market growth during the forecast period. However, the high cost of T-Cell therapy stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global T-Cell therapy Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to an increase in the occurrence of cancer cases, expansion in funding by private and governmental organizations and well-established research & commercialization basis. Furthermore, the growing senior population in North America has resulted in a higher frequency of cancer, increasing the need for appropriate therapies. According to the National Institute of Health in 2022, 1,918,030 new cancer cases and 609,360 cancer deaths are expected in the United States in 2020, with lung cancer, the leading cause of cancer mortality, accounting for nearly 350 fatalities each day. Asia Pacific is expected to grow significantly during the forecast period, owing to increased research and development in this region. Furthermore, the expansion of healthcare infrastructure and expanding government efforts accelerate the market's growth rate in this area. For example, the National Library of Medicine in China estimates that in 2022, there are expected to be approximately 88,249 new cases of leukaemia (50,213 male cases and 38,036 female cases).

Major market player included in this report are:

  • Bristol-Myers Squibb Company
  • Caribou Biosciences, Inc
  • Cartesian Therapeutics, Inc.
  • Johnson & Johnson Pvt. Ltd.
  • Cellectis, Inc.
  • Autolus Therapeutics
  • Immunocore Ltd.
  • Gilead Sciences, Inc.
  • Novartis AG
  • Celyad Oncology SA

Recent Developments in the Market:

  • In April 2022, The U.S. Food and Drug Administration (FDA) granted the Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus Therapeutics plc, a clinical-stage biopharmaceutical firm, to its lead gene therapy obecabatagene autoleucel (obe-cel). In the current FELIX Phase 2 investigation of adult relapsed/refractory B-Acute Lymphocytic Leukaemia, a CD19-directed autologous chimeric antigen receptor (CAR) T treatment is being examined.
  • In February 2022, CARVYKTI was approved by the US Food and Drug Administration (FDA) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Global T-Cell therapy Market Report Scope:

  • Historical Data: 2020 - 2021
  • Base Year for Estimation: 2022
  • Forecast period: 2023-2030
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Type, Indication, End Use, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

  • CAR T-Cell therapy
  • T-Cell Receptor-Based

By Indication:

  • Lymphoma
  • Acute Lymphocytic Leukemia
  • Others

By End Use:

  • Hospitals
  • Cancer Treatment Centers

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. T-Cell therapy Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. T-Cell therapy Market, by Type, 2020-2030 (USD Billion)
    • 1.2.3. T-Cell therapy Market, by Indication, 2020-2030 (USD Billion)
    • 1.2.4. T-Cell therapy Market, by End Use, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global T-Cell therapy Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global T-Cell therapy Market Dynamics

  • 3.1. T-Cell therapy Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing High prevalence rate of cancer
      • 3.1.1.2. Growing Geriatric Population
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of T-Cell therapy
      • 3.1.2.2. Stringent Government Regulations
    • 3.1.3. Market Opportunities
      • 3.1.3.1. New product development
      • 3.1.3.2. Increase in the number of research and development activities

Chapter 4. Global T-Cell therapy Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global T-Cell therapy Market, by Type

  • 5.1. Market Snapshot
  • 5.2. Global T-Cell therapy Market by Type, Performance - Potential Analysis
  • 5.3. Global T-Cell therapy Market Estimates & Forecasts by Type 2020-2030 (USD Billion)
  • 5.4. T-Cell therapy Market, Sub Segment Analysis
    • 5.4.1. CAR T-Cell therapy
    • 5.4.2. T-Cell Receptor-Based

Chapter 6. Global T-Cell therapy Market, by Indication

  • 6.1. Market Snapshot
  • 6.2. Global T-Cell therapy Market by Indication, Performance - Potential Analysis
  • 6.3. Global T-Cell therapy Market Estimates & Forecasts by Indication 2020-2030 (USD Billion)
  • 6.4. T-Cell therapy Market, Sub Segment Analysis
    • 6.4.1. Lymphoma
    • 6.4.2. Acute Lymphocytic Leukemia
    • 6.4.3. Others

Chapter 7. Global T-Cell therapy Market, by End Use

  • 7.1. Market Snapshot
  • 7.2. Global T-Cell therapy Market by End Use, Performance - Potential Analysis
  • 7.3. Global T-Cell therapy Market Estimates & Forecasts by End Use 2020-2030 (USD Billion)
  • 7.4. T-Cell therapy Market, Sub Segment Analysis
    • 7.4.1. Hospitals
    • 7.4.2. Cancer Treatment Centers

Chapter 8. Global T-Cell therapy Market, Regional Analysis

  • 8.1. Top Leading Countries
  • 8.2. Top Emerging Countries
  • 8.3. T-Cell therapy Market, Regional Market Snapshot
  • 8.4. North America T-Cell therapy Market
    • 8.4.1. U.S. T-Cell therapy Market
      • 8.4.1.1. Type breakdown estimates & forecasts, 2020-2030
      • 8.4.1.2. Indication breakdown estimates & forecasts, 2020-2030
      • 8.4.1.3. End Use breakdown estimates & forecasts, 2020-2030
    • 8.4.2. Canada T-Cell therapy Market
  • 8.5. Europe T-Cell therapy Market Snapshot
    • 8.5.1. U.K. T-Cell therapy Market
    • 8.5.2. Germany T-Cell therapy Market
    • 8.5.3. France T-Cell therapy Market
    • 8.5.4. Spain T-Cell therapy Market
    • 8.5.5. Italy T-Cell therapy Market
    • 8.5.6. Rest of Europe T-Cell therapy Market
  • 8.6. Asia-Pacific T-Cell therapy Market Snapshot
    • 8.6.1. China T-Cell therapy Market
    • 8.6.2. India T-Cell therapy Market
    • 8.6.3. Japan T-Cell therapy Market
    • 8.6.4. Australia T-Cell therapy Market
    • 8.6.5. South Korea T-Cell therapy Market
    • 8.6.6. Rest of Asia Pacific T-Cell therapy Market
  • 8.7. Latin America T-Cell therapy Market Snapshot
    • 8.7.1. Brazil T-Cell therapy Market
    • 8.7.2. Mexico T-Cell therapy Market
  • 8.8. Middle East & Africa T-Cell therapy Market
    • 8.8.1. Saudi Arabia T-Cell therapy Market
    • 8.8.2. South Africa T-Cell therapy Market
    • 8.8.3. Rest of Middle East & Africa T-Cell therapy Market

Chapter 9. Competitive Intelligence

  • 9.1. Key Company SWOT Analysis
    • 9.1.1. Company 1
    • 9.1.2. Company 2
    • 9.1.3. Company 3
  • 9.2. Top Market Strategies
  • 9.3. Company Profiles
    • 9.3.1. Bristol-Myers Squibb Company
      • 9.3.1.1. Key Information
      • 9.3.1.2. Overview
      • 9.3.1.3. Financial (Subject to Data Availability)
      • 9.3.1.4. Product Summary
      • 9.3.1.5. Recent Developments
    • 9.3.2. Caribou Biosciences, Inc
    • 9.3.3. Cartesian Therapeutics, Inc.
    • 9.3.4. Johnson & Johnson Pvt Ltd.
    • 9.3.5. Cellectis, Inc.
    • 9.3.6. Autolus Therapeutics
    • 9.3.7. Immunocore Ltd.
    • 9.3.8. Gilead Sciences, Inc.
    • 9.3.9. Novartis AG
    • 9.3.10. Celyad Oncology SA

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption